Falling Threshold for Treatment of Borderline Elevated Thyrotropin Levels—Balancing Benefits and Risks
Peter Taylor(University Hospital of Wales), Colin Dayan(University of Birmingham), Caroline Minassian(University of London), Onyebuchi Okosieme(Cwm Taf University Health Board), Vijay Panicker(Sir Charles Gairdner Hospital), Ahmed Iqbal(University of Bristol), Adrian Sayers(University of Bristol), Rosemary Greenwood, William Hamilton(University of Exeter), Sara L. Thomas(London School of Hygiene & Tropical Medicine), Mohd Shazli Draman(Nilai University)
Cited by 299
Related Papers
Global epidemiology of hyperthyroidism and hypothyroidism
|Nature Reviews Endocrinology|2018|1.5k
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial
|The Lancet|2007|679
How long does a hip replacement last? A systematic review and meta-analysis of case series and national registry reports with more than 15 years of follow-up
|The Lancet|2019|595
The expanding role of primary care in cancer control
|The Lancet Oncology|2015|544